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ABSTRACT
Access to readily available autogenous tissue that regenerates bone would greatly improve clinical
care. We believe the osteogenic phenotype caused by mutations in ALK2 can be harnessed in
adipose-derived stem cells (ASCs) to improve bone tissue engineering. We set out to demonstrate
that ALK2 may serve as a novel target to (a) improve in vitro ASC osteogenic differentiation and
(b) enhance in vivo bone regeneration and calvarial healing. Transgenic mice were designed using
the Cre/lox system to express constitutively active ALK2 (caALK2) with ubiquitously inducible Cre ex-
pression after tamoxifen exposure. ASCs from caALK2+/2 and caALK22/2 (control) mice were ex-
posed to tamoxifen and assessed for pro-osteogenic gene expression, bone morphogenetic protein
(BMP) signaling, andosteogenic differentiation.Next,ASCs collected from these transgenicmicewere
analyzed in vivo using a calvarial defect model and analyzed bymicro-computed tomography (micro-
CT) and histology. ASCs from caALK2+/2mice had increased BMP signaling as demonstrated by up-
regulation of pSmad 1/5. ASCs from caALK2+/2 mice had enhanced bone signaling and osteogenic
differentiation comparedwith caALK22/2mice (n=4,p< .05). Transcriptionofpro-osteogenic genes
at day 7 was significantly higher in ASCs from caALK2-overexpressing mice (Alp, Runx2, Ocn, Opn)
(n=4,p< .05).Usingmicro-CTandhistomorphometry,we found thatbone formationwas significantly
higher inmice treatedwith caALK2-expressingASCs in vivo.Usinganovel transgenicmousemodel,we
show that expression of constitutively active ALK2 receptor results in significantly increased ASC os-
teogenic differentiation. Furthermore,wedemonstrate that this increased ASC differentiation can be
harnessed to improve calvarial healing. STEM CELLS TRANSLATIONAL MEDICINE 2014;3:1375–1380
INTRODUCTION
Bone autograft is currently the gold standard
for calvarial reconstruction; however, its use
is constrained by availability and donor site mor-
bidity. The use of autogenous adipose-derived
stem cells (ASCs) on a matrix scaffold offers a
promising alternative to autograft. Recent clinical
studies have attempted to augment the osteo-
genic microenvironment of scaffolds through di-
rect recombinant bone morphogenetic protein-2
(BMP-2) and BMP-7 application [1–3]. Results
have been mixed because BMP ligands can
have a catabolic effect on bone through expres-
sion of RANK ligand-osteoprotegerin pathway.
BMP-2 has been shown to induce osteoclasto-
genesis by upregulation of RANKL, and BMP7
applied to vertebral burst fractures causes bone
resorption [4].
PatientswithanR206HmutationinALK2,atype
I BMP receptor, develop fibrodysplasia ossificans
progressiva (FOP) because of hyperactivation of
the ALK2 receptor (caALK2) [5, 6]. This disease
is characterized by the formation of heterotopic
ossification in the soft tissues [5, 7]. Specifically,
BMP-7hasbeen shown tobind toand formacom-
plex with ALK2 and BMPR2, stimulating phos-
phorylation of Smad 1/5 by the kinase domain
of ALK2. Phosphorylated Smad 1/5 then translo-
cates to the nucleus, upregulating osteogenic
gene expression. In this study, we use the Cre/
lox system to induceexpressionof a constitutively
activated ALK2 (caALK2) by Q207D mutation in
mouse ASCs [8, 9]. We hypothesized that consti-
tutive activity of ALK2 signaling will improve the
osteogenic potential of osteopotent cells such
as ASCs.
MATERIALS AND METHODS
Animals
The construction of a transgenic mouse line of
conditionally expressed, constitutively active
ALK2Q207D (CAG-Z-EGFP-caALK2; referred to as
aDepartment of Surgery,
University of Michigan
Medical School, Ann Arbor,
Michigan, USA; bDivision of
Advanced Prosthodontics,
Biomaterials, and Hospital
Dentistry, University of
California, Los Angeles, Los
Angeles, California, USA;
cDepartment of Biologic and
Materials Sciences,University
of Michigan Dental School,
Ann Arbor, Michigan, USA;
dDepartment of Surgery,
Massachusetts General
Hospital, Boston,
Massachusetts, USA
Correspondence: Benjamin Levi,
M.D., Massachusetts General
Hospital, Department of Surgery,
21 Beacon Street, Boston,
Massachusetts 02108, USA.
Telephone: 847-571-6511;
E-Mail: benlevimd@gmail.com
ReceivedApril 12, 2014; accepted
for publication August 1, 2014;
first published online in SCTM
EXPRESS September 17, 2014.
©AlphaMed Press
1066-5099/2014/$20.00/0
http://dx.doi.org/
10.5966/sctm.2014-0082
STEM CELLS TRANSLATIONAL MEDICINE 2014;3:1375–1380 www.StemCellsTM.com ©AlphaMed Press 2014
TISSUE ENGINEERING AND REGENERATIVE MEDICINE
caALK2 hereafter) has been previously described [8]. Ubiquitin-
CreER mice (UBC hereafter), which express a tamoxifen-
inducible Cre recombinase ubiquitously under the control of
the ubiquitin promoter, were obtained from Jackson Labora-
tory (Bar Harbor, ME, http://www.jax.org). Cre activity is tran-
sient, but Cre expressed (not expressing) cells are positive for
green fluorescent protein (GFP), and thus tissue engraftment
of Cre recombined (which indicates higher BMP activity) cells
can be detected by GFP. Cre unrecombined cell can be detected
by nuclear localized b-galactosidase. We have previously
shown that implanted ASCs are traceable during the first 2
weeks after implantation [10]. All experiments involving the
use of animals were approved by the Institutional Animal Use
and Care Committee at the University of Michigan, Ann Arbor
(PRO0001553).
Isolation and Osteogenic Differentiation of Primary
Adipose-Derived Mesenchymal Cells
ASCs were harvested from the inguinal fat pads of mutant
(caALK2+/2; UBC+/2) and littermate control mice (caALK22/2;
UBC+/2, n = 4 per group) as previously described [11]. ASCs were
seeded and treated with osteogenic differentiation medium
(ODM) supplemented with 4-hydroxy tamoxifen (4OHT, 100
ng/ml; Sigma-Aldrich, St. Louis, MO, http://www.sigmaaldrich.
com) [11]. Early osteogenic differentiation was assessed by alka-
line phosphatase stain and quantification on day 7 [12]. Alizarin
red staining for bone mineral deposition and quantification was
completed at day 14 as previously described [13].
Quantitative Polymerase Chain Reaction
RNA was harvested from cells after 7 days in ODM using the
RNeasy Mini Kit (Qiagen, Germantown, MD, http://www.
qiagen.com), reverse transcription was performed with 1 mg
of RNA, and quantitative real-time polymerase chain reaction
was carried out as previously described [14, 15]. Specific pri-
mers for the genes of interest (Runx2, Osteocalcin [Ocn],
Osteopontin (Opn), Alkaline phosphatase [Alp]) were chosen
based on their PrimerBank sequence (Table 1).
Western Blot Analysis
Cells were lysed and protein was collected after 7 days in osteo-
genic differentiation medium and assayed with standard immu-
noblotting technique as previously described [14]. Antibodies
against phospho-Smad 1/5 and Smad 5 (Cell Signaling Technol-
ogy, Beverly, MA, http://www.cellsignal.com) were used. All pro-
teins were normalized with the loading controls (a-tubulin) and
quantified by densitometry [14].
Scaffold Creation
Hydroxyapatite-coatedpoly(lactic-co-glycolic acid) (PLGA) scaffolds
were fabricated from 85/15 poly(lactic-coglycolic acid) (inherent
viscosity = 0.61 dl/g; Birmingham Polymers, Birmingham, AL,
http://www.absorbables.com) by solvent casting and a particulate
leaching process as previously described [10].
Calvarial Defects
Nonhealing, critical-sized (4mm) calvarial defectswere created in
the right parietal bone of adult CD-1 (60 days old) mice as previ-
ously described [10]. Animals were split equally into four treat-
ment groups: (a) empty defects, in which a 4-mm defect was
created; (b) scaffold only, in which a scaffold without cells was
placed in the defect site; (c) scaffold with 150,000 caALK2+/2
ASCs after 4OHT induction; and (d) scaffold with 150,000
4-OHT-treated caALK22/2 ASCs (n = 5 per group). ASCs were
not preinduced with ODM prior to implantation.
Micro-CT Analysis
In vivo bone formation was assessed with longitudinal micro-
computed tomography (micro-CT) scans for 8 weeks. Images
were reconstructed, and bone volume formation was analyzed
using a calibrated imaging protocol as previously described.
Quantification was performed as previously described, selecting
for new, calcified bone with a Hounsfield radio density of 800 or
greater [14, 16].
Histologic Processing and Aniline Blue Staining
Eight weeks following defect creation and scaffold placement,
whole calvaria were dissected, fixed in neutral buffered formalin
overnight, decalcified in 19% EDTA solution, and processed for
paraffin embedding. Five-micrometer sections were made in
cross-section through the defect and stained for bone tissue with
aniline blue.
Statistical Analysis
Means and standard deviations were calculated from numerical
data, and statistical analysis was performed using an appropriate
analysis of variance. Equivariance was assessed with Levene’s
test, and a Welch correction was applied when indicated. Post
hoc analysis for more than two data sets was completed with
Tukey’s test with equivariant data or Games-Howell if Levene’s
test failed. In figures, bar graphs represent means, whereas error
bars represent one standard deviation. Significance was defined
as p, .05.
RESULTS
Verification of caALK-2 Phenotype
Genotyping was performed to verify the presence of the caALK2
(ALK2Q207D) gene (Fig. 1A). Concurrently, we observed signifi-
cantly increased phosphorylation of Smad 1/5 in those ASCs
from caALK2+/2 mutant mice verifying caALK2 activation
(Fig. 1B).
Table 1. Polymerase chain reaction primers
Gene Forward sequence Reverse sequence
mRunx2 GTGCGGTGCAAACTTTCTCC AATGACTCGGTTGGTCTCGG
mOcn CTGACAAAGCCTTCATGTCCAA GCGGGCGAGTCTGTTCACTA
mOpn GCACTCCAACTGCCCAAGA TTTTGGAGCCCTGCTTTCTG
mAlp TGAGCGACACGGACAAGA GGCCTGGTAGTTGTTGTGAG
mGapdh CAAGGTCATCCATGACAACTTTG GGCCATCCACAGTCTTCTGG
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Mesenchymal Stem Cells Expressing caALK2 Have
Increased Osteogenic Signaling In Vitro
Early osteogenic gene markers alkaline phosphatase (Alp) and
Runx-2 were 50 and 3 times higher, respectively, in caALK2
mutant ASCs (n = 4, p , .05) compared with littermate
caALK22/2 controls (Fig. 1C, 1D). Similarly, intermediate and
late gene markers of osteogenic differentiation Ocn and Opn
were also significantly elevated in caALK2 expressing ASCs
(n = 4, p , .05) (Fig. 1E, 1F).
MSCs That Express caALK2 Have Increased Osteogenic
Differentiation In Vitro
We next analyzed the effect of caALK2 expression on early and
late osteogenic differentiation of ASCs cultured in vitro. After 7
days in ODM, we noted significantly more alkaline phosphatase
staining and quantification of alkaline phosphatase enzyme in
ASCs expressing caALK2 (Fig. 2A, 2B). After 14 days of osteogenic
differentiation, we noted significantlymore bonemineral formed
by ASCs expressing caALK2 compared with control (alizarin red
stain) (Fig. 2C, 2D).
Scaffolds SeededWith ASCs Expressing caALK2 Enhance
Calvarial Healing
ASCs expressing caALK2 were seeded onto hydroxyapatite-
coated PLGA scaffolds. Wild-type ASCs without the ALK2Q207D
transgene were also seeded at the same density. We observed
significantly more bone regeneration in the calvarial defects that
had scaffolds seeded with caALK2+/2 ASCs than scaffolds with
caALK22/2 ASCs, scaffold alone or no scaffold (Fig. 3A, 3B). Con-
firmation of new bone formation was verified by histologic stain
with aniline blue (Fig. 4).
DISCUSSION
Here we demonstrate that caALK2 results in increased osteo-
genic signaling and osteogenic differentiation of ASCs without
supplementation with BMP ligand in vitro and in vivo. Our in-
terest in ALK2 stems from the fact that a known mutation con-
ferring increased ALK2 activity results in FOP [9]. Because no
additional signaling molecule or other stimulus is required,
the surrounding cells retain their original genotype. The end re-
sult of improved bony healing is evident based on the micro-CT
scans demonstrating bone formation only within the calvarial
defect.
Of note, the calvarial regeneration observed in this study
demonstrated less robust in vivo bone growth than suggested
by previous studies using human ASCs [14, 17]. This finding
may be due to the fact that human ASCs are more osteogenic
in vitro and in vivo than mouse ASCs [11]. Additional studies will
analyze whether our implanted cells undergo endochondral ossi-
ficationandwhether theearly cartilage regenerate is differentbe-
tween mutant and control cells.
Figure 1. caALK2 confers increased osteogenic signaling among adipose-derived stem cells (ASCs). (A): Genotyping results of cells from
caALK2+/2 and caALK22/2mice. The wild-type allele shown at the bottomwas evident in all samples, whereas the transgene for conditional
activation of constitutive caALK2 signaling was present only in caALK2+/2mice. (B):Western blot analysis of protein collected from caALK2+/2
and caALK22/2ASCsafter 7days of exposure toosteogenic differentiationmedium (ODM)and tamoxifen for phosphorylated (activated) Smad
1/5, Smad5, anda-tubulin (loading control). Immunoblottingwas quantified bydensitometry and showed significantlymore activation of Smad
signaling in the caALK2+/2 ASCs. (C–F): Quantitative polymerase chain reaction results for osteogenic genes alkaline phosphatase (Alp) (C),
Runx-2 (D), osteocalcin (Ocn) (E), andosteopontin (Opn) (F) in caALK2+/2and caALK22/2ASCs after 7days of exposure toODMand tamoxifen.
In the charts, the bars representmeans, and error bars represent one standard deviation (p,p, .05). Abbreviation: caALK2, constitutively active
ALK2.
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CONCLUSION
Injuries incurred during trauma and combat often involve exten-
sive traumatic damage to superficial and deep soft tissues of the
extremities, axial skeleton, and the craniofacial skeleton, requir-
ing extended hospitalization and prolonged debilitation. These
chronic complications can profoundly affect quality of life. Accel-
erated rehabilitation and reconstructionwith this technology, we
hope, can reduce hospitalization and forestall serious and chronic
complications such as infection, loss of function, and loss of limb.
We believe a strategy proven to elicit bony growth from a more
osteogenic ASC population is less disruptive to the surrounding
environment. The abundance of ASCs in human fat suggests that
these cells may be a valuable therapeutic agent if appropriately
manipulated. Our model for therapy is not limited to calvarial
defects andmayapply to longbone fractures, bonygaps following
trauma, and spinal fractures, all of which have seenmixed results
with addition of exogenous BMP.
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Figure 2. caALK2 activation results in increased in vitro bone formation. (A): ALP stain of caALK2+/2 and caALK22/2 adipose-derived stem
cells exposed to tamoxifen andODMfor 7days. Positive staining is pink and indicatesALP activity andosteogenic differentiation. Representative
microtiter wells are shown at the left with micrograph details shown at310 (scale bar = 200mm) and320magnification (scale bar = 100mm).
(B):Quantification of ALP activity normalized to total protein content in these cells. (C):Alizarin red stain of these cells after 14 days exposure to
osteogenic differentiationmediumand tamoxifen. Red staining indicates in vitro osteoid deposition. Representativemicrotiter wells are shown
at the left with micrograph details shown at 310 (scale bar = 200 mm) and 320 magnification (scale bar = 100 mm). (D): Colorimetric quan-
tification of solubilized alizarin red stain. In the charts, the bars represent means, and error bars represent one standard deviation (p, p, .05).
Abbreviations: ALP, alkaline phosphatase; caALK2, constitutively active ALK2.
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Figure 3. caALK2 expression on implanted scaffolds enhanced calvarial healing. (A): Representativemicro-computed tomography (micro-CT) recon-
structed images ofmouse calvarial defects with the following treatments: no scaffold, scaffold alone, scaffold with caALK22/2 adipose-derived stem
cells (ASCs),orscaffoldwithcaALK2+/2ASCs.Cellsweretreatedwithtamoxifenpriorto implantation intothescaffolds.Micro-CTscanswerecompleted
at 3, 6, and 8weeks following defect creation. In the images, purple coloration indicates healing of the defect (scale bar = 5mm). (B):Quantification of
new-growth bone volume in the defects at the various scan time points (p, p, .05; pp, p, .01). Abbreviation: caALK2, constitutively active ALK2.
Figure 4. Histologic analysis of calvarial defect treated with a scaffold with caALK22/2 or caALK2+/2 adipose-derived stem cells (ASCs). Represen-
tativemicro-computedtomographyreconstructed imagesofmousecalvarialdefects receivingscaffoldwithcaALK22/2orcaALK2+/2ASCsareshown
at the left (scale bar =5mm). Cross-sections through thedefectweremade, and representative slides that showed themostbone growthwere stained
with H&E or aniline blue. H&E panels at32 magnification (scale bar = 1 mm) are labeled with anatomic landmarks. Aniline blue panels at32 mag-
nification (scale bar = 1mm) and34magnification (scale bar = 500mm) exhibit bone staining in dark blue. New bone growth is outlined in red in the
detail panels, and red arrows indicate scaffold absent of new bone. Abbreviations: caALK2, constitutively active ALK2; H&E, hematoxylin and eosin.
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